Eisai at a Glance

A Leading Global Research and Development-Based Pharmaceutical Company Headquartered in Japan
Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing, distribution and marketing, with a strong focus on prescription medicines.

  • Over 75 years of history

  • More than 10,000 employees worldwide

  • ¥ 600.1 billion annual revenue (FY2017)

Eisai’s Global Network

Japan, Americas, China, EMEA, Asia
Revenue by Reporting Segment in FY2016:OverseasRevenue Ratio 45.2%, Japan 54.0%, Americas 21.7%, China 9.1%, EMEA 7.0%, Asia 6.4%, Other Business 1.7%
Number of Employees by Region (As of the end of FY2016), Consolidated Number of Employees 10,452, Japan 5,009, China 1,909, Americas 1,320, Asia 1,231, EMEA 983
  • More than 40 subsidiaries worldwide

  • 15 Drug Discovery, Research and Development, and Clinical Research Sites

  • 10 Production sites

Eisai’s Therapeutic Areas of Focus : Neurology and Oncology

Global Brands

Fycompa® - antiepileptic agent, BELVIQ® - antiobesity agent Halaven® - anticancer agent, Lenvima® - anticancer agent

Eisai has positioned neurology and oncology as its therapeutic areas of focus, where there are many diseases for which adequate treatments have yet to be established. In order to fulfill patients’ unmet needs, Eisai sets out a goal to be a “Medico Societal Innovator” or in other words, “a company that changes society through creating medicines and providing solutions” in its medium-term business plan “EWAY 2025”.

Neurology:Neurodegenerative disorders (Alzheimer's disease, etc.)Neurological disorders (epilepsy, etc.)
 Over 10 projects under development in the area of dementia Oncology:Anticancer therapies (breast cancer, thyroid cancer, etc.) Discovered and developed anticancer agents Lenvima and Halaven for treating multiple types of cancer

Eisai’s Vision for 2025 : To be a “Medico Societal Innovator”

  • 5 core approaches
  • Creation of Innovative Medicines

    to fulfill unmet medical needs

  • Partnerships

    to improve efficiency and productivity

  • Provision of Solutions

    to address gaps in infrastructure

  • Flexible Pricing Policies

    to reduce financial barriers to treatment

  • Access Strategies

    to deliver products to people who need them

Corporate Philosophy

We give first thought to patients and their families, and to increasing the benefits health care provides.

Eisai's corporate philosophy reflects our commitment to business activities aiming to increase the benefits to patients, their families, and consumers, who we clearly recognize as the key players in healthcare. This corporate philosophy is summarized by the term
“human health care (hhc)”.

All employees are recommended to spend 1% of
their working hours with patients

hhc human health care

Eisai’s Access to Medicines Initiatives

“Access to Medicines” is about ensuring that medicines and treatments are made available to the communities that need them. Eisai is promoting initiatives for improving access to medicines in developing and emerging countries.

27 countries 
1.41 billion DEC tablets
(As of June 2018)

Eisai is committed to supplying tablets free of charge from its Vizag Plant in India to 250 million people at risk in lymphatic filariasis endemic countries through the World Health Organization until the disease is completely eliminated in these countries.

Social Recognition (as of September 2017)

  • MEMBER OF Dow Jones Sustainability Indices In Collaboration with RobecoSAM
  • RobecoSAM sustainability Award Industry Mover 2017
  • MSCI 2017 Constituent MSCI Japan ESG Select Leaders Index
  • FTSE4Good
  • FTSE Blossom Japan
  • Access to Medicine Index